| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 02/08/2001 | WO2001009305A2 Purine metabolism genes in plants |
| 02/08/2001 | WO2001009304A2 Polynucleotides encoding aminolevulinic acid biosynthetic enzymes |
| 02/08/2001 | WO2001009302A2 Agrobacterium-mediated plant transformation method |
| 02/08/2001 | WO2001009301A2 Nucleic acids and polypeptides of invertebrate twik channels and methods of use |
| 02/08/2001 | WO2001009300A2 Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
| 02/08/2001 | WO2001009299A2 Modified plants |
| 02/08/2001 | WO2001009297A1 A method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 02/08/2001 | WO2001009296A1 Nucleic acid sequences encoding polyenoic fatty acid isomerase and uses thereof |
| 02/08/2001 | WO2001009295A1 Enzymes with beta-(1,6)-endoglucanase activity |
| 02/08/2001 | WO2001009293A2 Mammalian adhesion protease peptides |
| 02/08/2001 | WO2001009292A2 Sentrin-specific human proteases senp1-3 |
| 02/08/2001 | WO2001009291A1 Attenuated influenza virus useful as vaccine |
| 02/08/2001 | WO2001009286A1 Metabolic engineering of amino acid production |
| 02/08/2001 | WO2001009283A2 Chimeric receptors and their uses |
| 02/08/2001 | WO2001009193A1 Chimeric polypeptides, method for production and uses thereof |
| 02/08/2001 | WO2001009192A1 Human monoclonal antibodies to prostate specific membrane antigen |
| 02/08/2001 | WO2001009189A2 Compositions and methods for the treatment of tumors |
| 02/08/2001 | WO2001009188A1 Binding moieties for fibrin |
| 02/08/2001 | WO2001009187A2 Human monoclonal antibodies to her2/neu |
| 02/08/2001 | WO2001009186A2 Therapeutic compounds comprised of anti-fc receptor binding agents |
| 02/08/2001 | WO2001009185A2 Transmembrane transport proteins, nucleic acids encoding them and uses therefor |
| 02/08/2001 | WO2001009184A1 Human g-protein coupled receptor |
| 02/08/2001 | WO2001009183A2 Polymorphisms in the human mdr-1 gene and applications thereof |
| 02/08/2001 | WO2001009182A1 Prolactin-releasing peptide and method for regulating autonomic functions and treating pain |
| 02/08/2001 | WO2001009179A1 Moraxella cattarrhalis basb114 antigens and uses thereof |
| 02/08/2001 | WO2001009178A2 Human chaperone proteins |
| 02/08/2001 | WO2001009177A2 Affinity fluorescent proteins and uses thereof |
| 02/08/2001 | WO2001009176A2 Mammalian cytokines; related reagents |
| 02/08/2001 | WO2001009175A2 Plant defensin variants with modified cystein residues |
| 02/08/2001 | WO2001009174A2 Plant defensin variants |
| 02/08/2001 | WO2001009171A1 Novel tachykinin peptides, precursor peptides thereof and genes encoding the same |
| 02/08/2001 | WO2001009160A1 Nucleic acid ligands to cd40ligand |
| 02/08/2001 | WO2001009159A1 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins |
| 02/08/2001 | WO2001009158A1 Conditional-selex |
| 02/08/2001 | WO2001009157A1 High affinity vascular endothelial growth factor (vegf) receptor nucleic acid ligands and inhibitors |
| 02/08/2001 | WO2001009156A1 HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS |
| 02/08/2001 | WO2001009155A1 Cloning of the streptomyces avermitilis genes for glycosylation of avermectin aglycones |
| 02/08/2001 | WO2001008802A1 Low volume chemical and biochemical reaction system |
| 02/08/2001 | WO2001008710A1 Gene expression with covalently modified polynucleotides |
| 02/08/2001 | WO2001008708A2 Enhanced delivery via serpin enzyme complex receptor ligands |
| 02/08/2001 | WO2001008707A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 02/08/2001 | WO2001008703A1 Recombinant rsv virus expression systems and vaccines |
| 02/08/2001 | WO2001008702A2 Immunotherapy in hiv infected persons using vaccines after multi-drug treatment |
| 02/08/2001 | WO2001008701A2 Invasive bacteria based viral vaccines |
| 02/08/2001 | WO2001008699A1 Methods of inhibiting osteoclastogenesis |
| 02/08/2001 | WO2001008636A2 Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| 02/08/2001 | WO2001008635A2 Calcium channel transport polynucleotides, polypeptides, and antibodies |
| 02/08/2001 | WO2001008634A2 Polynucleotide encoding a human serine protease |
| 02/08/2001 | WO2000076540A3 Streptococcus pneumoniae proteins and vaccines |
| 02/08/2001 | WO2000075317A3 Compositions and methods for the treatment of tumor |
| 02/08/2001 | WO2000075310A8 Interleukin-1-receptor associated kinase-3 (irak3) |
| 02/08/2001 | WO2000070057A3 Mutant 1,3-propanediol dehydrogenase |
| 02/08/2001 | WO2000070019A3 Process of rapid variety-independent plant transformation |
| 02/08/2001 | WO2000070017A3 Methods using of fab i and compounds modulating fab i activity |
| 02/08/2001 | WO2000069894A3 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
| 02/08/2001 | WO2000068405A3 Plant defensins |
| 02/08/2001 | WO2000068261A3 Attenuated microorganisms for the treatment of infection |
| 02/08/2001 | WO2000067700A3 Recombinant vaccine against botulinum neurotoxin |
| 02/08/2001 | WO2000066771A3 Diagnostic sequencing by a combination of specific cleavage and mass spectrometry |
| 02/08/2001 | WO2000066724A3 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna |
| 02/08/2001 | WO2000065039A3 Identification of dna control elements responsive to specific stimuli |
| 02/08/2001 | WO2000063667A3 Methods for identifying modulators of n-type ion channel inactivation |
| 02/08/2001 | WO2000063426A3 Compound screening methods |
| 02/08/2001 | WO2000063406A3 Adenoviral vectors having nucleic acids encoding immunomodulatory molecules |
| 02/08/2001 | WO2000063247A3 Osteopontin-derived chemotactic and inhibitory agents and uses therefor |
| 02/08/2001 | WO2000063230A3 49 human secreted proteins |
| 02/08/2001 | WO2000062815A3 Novel pharmaceutical composition suitable for gene therapy |
| 02/08/2001 | WO2000061772A3 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| 02/08/2001 | WO2000061768A3 Preparation of biologically active molecules |
| 02/08/2001 | WO2000061756A3 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| 02/08/2001 | WO2000058487A3 Insect viral vectors and uses thereof |
| 02/08/2001 | WO2000058471A3 Multidrug resistance associated proteins and uses thereof |
| 02/08/2001 | WO2000057180A3 Use of lna in mass spectrometry |
| 02/08/2001 | WO2000056916A3 Detection of mutations in genes by specific lna primers |
| 02/08/2001 | WO2000055311A3 Gene modification by homologous recombination |
| 02/08/2001 | WO2000053773A3 Methods for mitochondrial gene therapy |
| 02/08/2001 | WO2000053758A3 Compositions and methods for the treatment of immune related diseases |
| 02/08/2001 | WO2000053755A3 Compositions and methods for the treatment of tumor |
| 02/08/2001 | WO2000041524A3 Isothermal amplification of dna |
| 02/08/2001 | WO2000040715A3 Improved nucleic acid cloning |
| 02/08/2001 | DE19937230A1 Chimäre Proteine Chimeric proteins |
| 02/08/2001 | DE19936563A1 Tumorassoziiertes Antigen Tumor-associated antigen |
| 02/08/2001 | DE19935772A1 Verfahren zur relativen Quantifizierung der Methylierung von Cytosin Basen in amplifizierten Nukleinsäurefragmenten Method for the relative quantification of methylation of cytosine bases in nucleic acid amplified fragments |
| 02/08/2001 | DE19935756A1 Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation Nucleic acid molecule covalently closed for immunostimulation |
| 02/08/2001 | DE19935749A1 Verfahren zur Chrakterisierung von Nukleinsäurefragmenten Method for Chrakterisierung of nucleic acid fragments |
| 02/08/2001 | DE19935303A1 Oligonukleotide zur Inhibierung der Expression von humanem eg5 Oligonucleotides for inhibiting the expression of human Eg5 |
| 02/08/2001 | DE19935302A1 Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen Conjugates and methods for their preparation and their use for transporting molecules across biological membranes |
| 02/08/2001 | DE19935268A1 N-Acetylaminosäureracemase N-acetylamino acid |
| 02/08/2001 | DE19935106A1 DNA-Sequenzen, die Lipopeptidsynthasen kodieren DNA sequences encoding Lipopeptidsynthasen |
| 02/08/2001 | DE19935087A1 DNA-Sequenzen, die Oxygenasen kodieren DNA sequences encoding oxygenases |
| 02/08/2001 | DE19935086A1 DNA-Sequenzen, die Typ II (xcp) Sekretionssysteme kodieren DNA sequences encoding type II (xcp) secretion |
| 02/08/2001 | DE19933362A1 Verfahren zur Herstellung von L-Aminosäuren aus ihren racemischen N-Acetyl-D,L-Derivaten durch enzymatische Racemat-Spaltung mittels isolierter, rekombinanter Enzyme A method for producing L-amino acids from their racemic N-acetyl-D, L derivatives by enzymatic resolution by means of isolated, recombinant enzymes |
| 02/08/2001 | DE19904800C1 Partikel zur Gentherapie Particles for gene therapy |
| 02/08/2001 | DE10019006A1 Neuartiger adenoviraler Vektor für den Gentransfer, seine Anwendung und seine Herstellung Novel adenoviral vector for gene transfer, its application and its preparation |
| 02/08/2001 | CA2820314A1 Vaccine composition |
| 02/08/2001 | CA2820271A1 Vaccine composition |
| 02/08/2001 | CA2756675A1 A method for the determination of allelic imbalance by nucleic acid amplification assays |
| 02/08/2001 | CA2756673A1 Digital amplification |
| 02/08/2001 | CA2697207A1 Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications |
| 02/08/2001 | CA2391682A1 Novel uses of abca-type transporters |